PRA HEALTH SCIENCES
(NASDAQ: PRAH)

PRA Health Sciences, Inc. (PRA) is a global contract research organization (CRO), which provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company has therapeutic expertise in oncology, central nervous system, inflammation and infectious diseases. PRA offers clinical development services, which include both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. The Company�s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company has performed approximately 2,300 clinical trials across the world, and has worked on more than 100 marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to United States Food and Drug Administration(FDA) or international regulatory approval of more than 45 drugs.

165.210

- (-%)
Range - - -   (-%)
Open -
Previous Close 165.210
Bid Price 165.850
Bid Volume -
Ask Price 175.000
Ask Volume -
Volume -
Value -
Remark
Delayed prices. Updated at 01 Jul 2021 04:00.
Data powered by
View All Events

About PRA HEALTH SCIENCES INC

PRA Health Sciences, Inc. (PRA) is a global contract research organization (CRO), which provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company has therapeutic expertise in oncology, central nervous system, inflammation and infectious diseases. PRA offers clinical development services, which include both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. The Company�s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company has performed approximately 2,300 clinical trials across the world, and has worked on more than 100 marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to United States Food and Drug Administration(FDA) or international regulatory approval of more than 45 drugs.

Please login to view stock data and analysis